CN103826655A - 胰岛淀粉样多肽及其衍生物和用途 - Google Patents

胰岛淀粉样多肽及其衍生物和用途 Download PDF

Info

Publication number
CN103826655A
CN103826655A CN201280036795.0A CN201280036795A CN103826655A CN 103826655 A CN103826655 A CN 103826655A CN 201280036795 A CN201280036795 A CN 201280036795A CN 103826655 A CN103826655 A CN 103826655A
Authority
CN
China
Prior art keywords
substituted
unsubstituted
compound
polypeptide
lys
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201280036795.0A
Other languages
English (en)
Chinese (zh)
Inventor
C.孙
M.P.萨曼特
S.內拉维特拉
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Original Assignee
Amylin Pharmaceuticals LLC
AstraZeneca Pharmaceuticals LP
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Amylin Pharmaceuticals LLC, AstraZeneca Pharmaceuticals LP filed Critical Amylin Pharmaceuticals LLC
Publication of CN103826655A publication Critical patent/CN103826655A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/56—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule
    • A61K47/59—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes
    • A61K47/60—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic macromolecular compound, e.g. an oligomeric, polymeric or dendrimeric molecule obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyureas or polyurethanes the organic macromolecular compound being a polyoxyalkylene oligomer, polymer or dendrimer, e.g. PEG, PPG, PEO or polyglycerol
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Genetics & Genomics (AREA)
  • Endocrinology (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Emergency Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Cardiology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
CN201280036795.0A 2011-05-25 2012-05-24 胰岛淀粉样多肽及其衍生物和用途 Pending CN103826655A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161489781P 2011-05-25 2011-05-25
US61/489781 2011-05-25
PCT/US2012/039431 WO2012162542A1 (en) 2011-05-25 2012-05-24 Amylin peptides and derivatives and uses thereof

Publications (1)

Publication Number Publication Date
CN103826655A true CN103826655A (zh) 2014-05-28

Family

ID=47217749

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201280036795.0A Pending CN103826655A (zh) 2011-05-25 2012-05-24 胰岛淀粉样多肽及其衍生物和用途

Country Status (17)

Country Link
US (1) US20140221287A1 (enExample)
EP (1) EP2714067A1 (enExample)
JP (1) JP2014516049A (enExample)
KR (1) KR20140045433A (enExample)
CN (1) CN103826655A (enExample)
BR (1) BR112013030067A2 (enExample)
CA (1) CA2837104A1 (enExample)
CL (1) CL2013003377A1 (enExample)
CO (1) CO6821894A2 (enExample)
EA (1) EA201391763A1 (enExample)
IL (1) IL229449A0 (enExample)
MX (1) MX2013013802A (enExample)
PH (1) PH12013502385A1 (enExample)
SG (1) SG194998A1 (enExample)
TN (1) TN2013000491A1 (enExample)
WO (1) WO2012162542A1 (enExample)
ZA (1) ZA201309679B (enExample)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104327162A (zh) * 2014-09-28 2015-02-04 苏州普罗达生物科技有限公司 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用
CN106687474A (zh) * 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法
CN112074289A (zh) * 2018-04-25 2020-12-11 詹森药业有限公司 硫醚环状肽胰淀素受体调节剂

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2068909B1 (en) 2007-03-30 2012-04-25 Ambrx, Inc. Modified fgf-21 polypeptides and their uses
KR102854572B1 (ko) 2014-10-24 2025-09-02 브리스톨-마이어스 스큅 컴퍼니 변형된 fgf-21 폴리펩티드 및 그의 용도
US11028137B2 (en) 2017-02-01 2021-06-08 The Research Foundation For The State University Of New York Mutant islet amyloid polypeptides with improved solubility and methods for using the same
JP7652422B2 (ja) 2018-11-02 2025-03-27 ベイジン ブイディージェイバイオ カンパニー， リミテッド 修飾されたｃｔｌａ４およびその使用方法
TW202400632A (zh) 2021-03-03 2024-01-01 美商美國禮來大藥廠 長效澱粉素受體促效劑及其用途
IL312672A (en) * 2021-11-10 2024-07-01 I2O Therapeutics Inc Ionic liquid compositions
CN119278209A (zh) 2022-05-27 2025-01-07 杭州先为达生物科技股份有限公司 人胰淀素类似物、其衍生物及用途

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009034118A1 (en) * 2007-09-11 2009-03-19 Novo Nordisk A/S Stable formulations of amylin and its analogues
CN101400698A (zh) * 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
CN101855240A (zh) * 2007-09-11 2010-10-06 诺沃-诺迪斯克有限公司 改进的胰岛淀粉样多肽衍生物
CN101918026A (zh) * 2007-11-20 2010-12-15 Ambrx公司 经修饰胰岛素多肽和其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2233497A3 (en) * 2004-02-11 2011-01-12 Amylin Pharmaceuticals, Inc. Amylin family peptides and methods for making and using them
WO2006086769A2 (en) * 2005-02-11 2006-08-17 Amylin Pharmaceuticals, Inc. Gip analog and hybrid polypeptides with selectable properties

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101400698A (zh) * 2006-03-15 2009-04-01 诺沃-诺迪斯克有限公司 胰岛淀粉样多肽衍生物
WO2009034118A1 (en) * 2007-09-11 2009-03-19 Novo Nordisk A/S Stable formulations of amylin and its analogues
CN101855240A (zh) * 2007-09-11 2010-10-06 诺沃-诺迪斯克有限公司 改进的胰岛淀粉样多肽衍生物
CN101918026A (zh) * 2007-11-20 2010-12-15 Ambrx公司 经修饰胰岛素多肽和其用途

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106687474A (zh) * 2014-09-04 2017-05-17 诺和诺德股份有限公司 新型胰淀素和降钙素受体激动剂
CN104327162A (zh) * 2014-09-28 2015-02-04 苏州普罗达生物科技有限公司 一种胰岛素淀粉样多肽抑制剂及其制备方法、应用
CN112074289A (zh) * 2018-04-25 2020-12-11 詹森药业有限公司 硫醚环状肽胰淀素受体调节剂
CN110467666A (zh) * 2019-09-17 2019-11-19 湖北强耀生物科技有限公司 一种新型胰岛淀粉样多肽的合成方法

Also Published As

Publication number Publication date
IL229449A0 (en) 2014-01-30
WO2012162542A1 (en) 2012-11-29
KR20140045433A (ko) 2014-04-16
CA2837104A1 (en) 2012-11-29
MX2013013802A (es) 2014-04-25
PH12013502385A1 (en) 2014-01-13
US20140221287A1 (en) 2014-08-07
EA201391763A1 (ru) 2014-04-30
NZ618526A (en) 2015-09-25
CO6821894A2 (es) 2013-12-31
BR112013030067A2 (pt) 2016-11-29
ZA201309679B (en) 2016-10-26
CL2013003377A1 (es) 2014-07-04
SG194998A1 (en) 2013-12-30
EP2714067A1 (en) 2014-04-09
TN2013000491A1 (en) 2015-03-30
JP2014516049A (ja) 2014-07-07

Similar Documents

Publication Publication Date Title
CN103826655A (zh) 胰岛淀粉样多肽及其衍生物和用途
JP6412183B2 (ja) 作用持続時間が増した改変ポリペプチド
US20140221282A1 (en) Long duration dual hormone conjugates
CN101389648B (zh) 肽胃泌酸调节素衍生物
JP6618854B2 (ja) 作用持続期間が増大し、免疫原性が減少した操作されたポリペプチド
US20140249076A1 (en) Amylin-calcitonin chimeric peptides conjugated to duration enhancing moieties
US20150111246A1 (en) Site-specific enzymatic modification of exendins and analogs thereof
US9175061B2 (en) Protein conjugates and methods for their preparation
US9217022B2 (en) GLP-1 receptor agonist compounds having stabilized regions
US9018160B2 (en) Peptide tyrosine tyrosine analogues
JP2023506952A (ja) インクレチン類似体およびその使用
KR20130036290A (ko) 추가 이황화 결합을 함유하는 인슐린 유도체
JP2017509698A (ja) プレプログルカゴンから誘導可能なペプチドホルモン類似体
JP2025178483A (ja) ポリペプチドを含む医薬組成物
CN104918954A (zh) N-末端电荷发生变化的胰岛素分泌肽衍生物
AU2003273761A1 (en) Glucagon-like peptide-2 variants
HK1198008A (en) Amylin peptides and derivatives and uses thereof
AU2012258714A1 (en) Amylin peptides and derivatives and uses thereof
NZ618526B2 (en) Amylin peptides and derivatives and uses thereof

Legal Events

Date Code Title Description
C06 Publication
PB01 Publication
C10 Entry into substantive examination
SE01 Entry into force of request for substantive examination
REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1198008

Country of ref document: HK

C02 Deemed withdrawal of patent application after publication (patent law 2001)
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20140528

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1198008

Country of ref document: HK